Public Policy Resources

Share

As a recognized expert in cancer health policy, ACS CAN develops reports, white papers, testimony, fact sheets, regulatory comment letters and public policy on a wide range of issues related to preventing cancer and improving the health care system for persons with cancer and survivors.  We encourage you to use this resource to learn more about our issue priorities and policy work. If you can't find something you need, you may contact us by using our contact form and selecting Policy Resources from the drop-down menu.

Search for Resources

FILTER BY:

Photo of female cancer patient

Patient Quality of Life

ACS CAN advocates for policies that improve the lives of cancer patients by making treatment of their pain and other symptoms and coordination of their care standard protocol throughout their treatment for cancer, starting at the point of diagnosis.
 

Featured Resources

 

ACS CAN submitted comments to FDA regarding questions relevant to the newly formed FDA Opioid Policy Steering Committee.

The Pain & Policy Studies Group (PPSG) at the University of Wisconsin, the American Cancer Society and the American Cancer Society Cancer Action Network (ACS CAN) have released a report grading states on their enactment of balanced policies to enhance the delivery of effective pain management

This scorecard evaluates balance between needed access to pain medication for cancer patients and efforts to reduce misuse and abuse of pain medications.

Photo of ACS CAN Volunteers at Advocacy Event to Support Cancer Research Funding

Research, Funding and Drug Development

Improvements in outcomes for cancer patients require continued research and innovation.  ACS CAN advocates for robust federal funding for cancer research, as well as research and drug approval policies that accelerate the development of new treatments while still ensuring patient safety.

ACS CAN supports the coverage of FDA-approved NGS panels, and also supports the coverage of panels used as part of NCI clinical trials.  CMS is encouraged to reconsider limitations on patient eligibility and is urged to create clear and achievable requirments for evidence development. 

The costs of conducting cancer research include a variety of specific items ranging from researcher salaries, to laboratory supplies, along with utilities and maintenance.  

ACS CAN along with over 80 other patient organizations provided support and feedback to FDA regarding the creation of an Office of Patient Affairs that would help coordinate patient involvement at FDA.

Photo of ACS CAN Volunteers participating in health care reform Lobby Day event

Access to Health Care

ACS CAN advocates for policies that provide access to treatments and services people with cancer need for their care - including those who may be newly diagnosed, in active treatment and cancer survivors.

A Section 1115 Demonstration Waiver gives states flexibility to design and improve upon their Medicaid programs through pilot or demonstration projects.

On January 16, 2018, ACS CAN filed comments in response to CMS’ proposed rule implementing changes to the Medicare Part C and Part D programs. ACS CAN commented on a number of proposed policies:

A Section 1115 Demonstration Waiver gives states flexibility to design and improve upon their Medicaid programs through pilot or demonstration projects.

Photo of Making Strides Against Breast Cancer Event Participant

Prevention and Early Detection

ACS CAN advocates for public policies that can prevent nearly half of all cancer deaths by ensuring access to recommended cancer screenings, protecting the public from skin cancer risk, reducing tobacco use and exposure to secondhand smoke and supporting people in increasing physical activity, eating a healthy diet, and managing their weight.

The economic model developed jointly by the Campaign for Tobacco-Free Kids (TFK), the American Cancer Society Cancer Action Network (ACS CAN), and Tobacconomics  (a program of the University of Illinois at Chicago) projects the increase in state revenues, public health benefits, and health care cost savings resulting from increases in state cigarette tax rates.  

For the past 19 years – since the states settled their lawsuits against the major tobacco companies in November 1998 – we have issued annual reports assessing how well the states have kept their promise to use a significant portion of their settlement funds to combat tobacco use in the United Sta

ACS CAN submitted comments to the U.S. Food and Drug Administration on their proposed rule to delay the compliance date for the updated Nutrition Facts label by 18 months.